抗体依赖性细胞介导的细胞毒性
抗体
基督教牧师
单克隆抗体
阿勒姆图祖马
癌症研究
药理学
医学
免疫学
哲学
神学
作者
Alain Beck,Janice M. Reichert
出处
期刊:mAbs
[Informa]
日期:2012-06-28
卷期号:4 (4): 419-425
被引量:198
摘要
Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of mAbs. The recent approval in Japan of mogamulizumab (POTELIGEO®), the first glyco-engineered antibody to reach the market, is a landmark in the field of therapeutic antibodies. Mogamulizumab is a humanized mAb derived from Kyowa Hakko Kirin’s POTELLIGENT® technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. The approval was granted April 30, 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI